The Ochsner CCOP, an enthusiastic, multicomponent clinical research unit, was originally funded during CCOP I, and competitively renewed during CCOP II. The Ochsner CCOP has integrated the resources of a major medical center, the Ochsner Medical Institutions, with community-based oncologists in the true spirit of the CCOP RFA. Participation of Ochsner CCOP investigators into all aspects of research base activities has resulted in a modest but significant CCOP bibliography of ten publication which are included in LIterature Cited. During CCOP I, the Ochsner CCOP worked vigorously to develop an effective network in southern Louisiana and southern Mississippi for participation in cancer treatment protocols. During CCOP II, the Ochsner CCOP further enlarged its network to include the New Orleans Children's Hospital which has expanded the scope from an adult only CCOP to one with an active pediatric component. Also during CCOP II, there was a commitment to the development of the basic mechanisms for cancer control research. This was accomplished by the recruitment of a Cancer Control Coordinator, and the involvement of non-oncology physicians into cancer control trials. The Ochsner CCOP has evolved into the largest cancer clinical trials program in the state of Louisiana, and a major clinical trials force in the state of Mississippi. The goals of the Ochsner CCOP for the new grant period are four-fold: 1. To increase our already high accrual to cancer treatment protocols. This will be accomplished through the now increased oncology staff at three components: Ochsner Clinic of New Orleans, Ochsner Clinic of Baton Rouge, and Biloxi, Mississippi, and through the addition of a new component, the Methodist Cancer Center of East New Orleans. 2. To further expand our cancer control efforts with emphasis on increased participation of our Mississippi components. 3. To enhance minority participation in CCOP activities by the inclusion of a new CCOP components, Methodist Cancer Center of East New Orleans. The patient mix at the methodist Cancer Center is greater than 50% minority group patients. 4. To consolidate the CCOP research efforts by emphasizing participation in three major research bases. The primary research base is NCCTG, which includes non-conflicting ECOG protocols. The other major research bases are NSABP and POG. The Ochsner CCOP will also be affiliated with M.D. Anderson primarily for cancer control, but selected non-conflicting cancer treatment protocols will be utilized. The Ochsner CCOP has a proven track record as an efficient, disciplined team and plans to continue to contribute significantly to the NCI's clinical research efforts. The Ochsner CCOP will continue to emphasize quality, quantity (high accrual) and economy (low cost per case accrued).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (SRC (54))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ochsner Clinic Foundation
New Orleans
United States
Zip Code
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Gonsalves, Wilson I; Mahoney, Michelle R; Sargent, Daniel J et al. (2014) Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 106:
Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Huang, Jocelin; Nair, Suresh G; Mahoney, Michelle R et al. (2014) Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 13:100-9
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Sticca, Robert P; Alberts, Steven R; Mahoney, Michelle R et al. (2013) Current use and surgical efficacy of laparoscopic colectomy in colon cancer. J Am Coll Surg 217:56-62; discussion 62-3
Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92
Lavoie Smith, Ellen M; Barton, Debra L; Qin, Rui et al. (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22:2787-99

Showing the most recent 10 out of 72 publications